RESEARCH ARTICLE

REVISED Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq [version 2; peer review: 2 approved]

Previously titled: Spectrum of Sellar and Parasellar Region Lesions: A retrospective study from Basrah, Iraq

Abbas Ali Mansour , Ali Hussain Ali Alhamza, Ammar Mohammed Saeed Abdullah Almomin, Ibrahim Abbood Zaboon, Nassar Taha Yaseen Alibrahim, Rudha Naser Hussein, Muayad Baheer Kadhim, Haider Ayad Yassin Alidrisi , Hussein Ali Nwayyir , Adel Gassab Mohammed , Dheyaa Kadhim Al-Waeli, Ibrahim Hani Hussein

Faiha Specialized Diabetes, Endocrine and Metabolism Center (FDEMC), Diabetes, Endocrine and Metabolism Division, Department of Medicine, Basrah College of Medicine, Hattin post office. P.O Box: 142, Basrah, 61013, Iraq

v2 First published: 06 Apr 2018, 7:430
<https://doi.org/10.12688/f1000research.13632.1>
 Latest published: 22 Jun 2018, 7:430
<https://doi.org/10.12688/f1000research.13632.2>

Abstract

Background: Pituitary disorders spectrum includes a wide variety of diseases. This study aimed at a comprehensive description of such disorders for patients from Faiha Specialized Diabetes, Endocrine and Metabolism Center (FDEMC) in Basrah (Southern Iraq).

Methods: Retrospective data analysis of FDEMC for the period from January 2012 through June 2017. We included all patients with pituitary disorders who have MRI pituitary.

Results: The pituitary disorders were more common among women. Those with macroadenoma were older than those with microadenoma with nearly equal gender prevalence of macroadenoma. Pituitary adenoma constituted the bulk of pituitary disorders in this registry (67.2%). Growth hormone secreting adenoma were the commonest adenoma seen in 41.0% followed by clinically non-functioning pituitary adenoma (NFPA) in 31.4% and prolactinoma in 26.9%. About 64.8% of pituitary adenoma was macroadenoma. Macroadenoma was seen in 73.4% of growth hormone secreting adenoma, 61.2% in NFPA and 62.0% of prolactinoma (of them six were giant prolactinoma).

Conclusion: Pituitary adenoma constituted the bulk of pituitary disorders in Basrah, growth hormone secreting adenoma is the commonest adenoma followed by NFPA and prolactinoma due to referral bias. A change in practice of pituitary adenoma treatment is needed.

Open Peer Review

Approval Status

	1	2
version 2 (revision) 22 Jun 2018		 view
version 1 06 Apr 2018	 view	 view

1. **Abdul Al-Toma**, St Antonius Hospital, Nieuwegein, The Netherlands
2. **Khaled Mohammed Al-Dahmani** , Tawam Hospital, Al Ain, United Arab Emirates
United Arab Emirates University, Abu Dhabi, United Arab Emirates

Any reports and responses or comments on the article can be found at the end of the article.

Keywords

Sellar and parasellar region lesions, pituitary disease, pituitary adenoma, classification, epidemiology.

Corresponding author: Abbas Ali Mansour (abbas.mansour@fdemc.iq)

Author roles: **Mansour AA:** Conceptualization, Data Curation, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Alhamza AHA:** Investigation, Methodology, Project Administration; **Almomin AMSA:** Project Administration, Resources, Visualization, Writing – Original Draft Preparation; **Zaboony IA:** Data Curation, Investigation, Validation, Visualization; **Alibrahim NTY:** Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Hussein RN:** Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation; **Kadhim MB:** Conceptualization, Formal Analysis, Resources, Software; **Alidrisi HAY:** Investigation, Supervision, Validation, Writing – Review & Editing; **Nwayyir HA:** Investigation, Resources, Software, Supervision, Visualization; **Mohammed AG:** Investigation, Supervision, Visualization, Writing – Original Draft Preparation; **Al-Waeli DK:** Data Curation, Funding Acquisition, Investigation, Validation; **Hussein IH:** Data Curation, Formal Analysis, Funding Acquisition, Software, Validation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Mansour AA *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Mansour AA, Alhamza AHA, Almomin AMSA *et al.* **Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq [version 2; peer review: 2 approved]** F1000Research 2018, 7:430 <https://doi.org/10.12688/f1000research.13632.2>

First published: 06 Apr 2018, 7:430 <https://doi.org/10.12688/f1000research.13632.1>

REVISED Amendments from Version 1

- The research title has been changed based on referee suggestions
- Inclusion criteria has been made more clear
- We have corrected typos
- We clarify that the total number can't be 232 because some may have more than one diagnosis
- Miscellaneous cases has been clarified
- Number in table 3 made more clear
- Conclusion has been clarified

See referee reports

Introduction

Sellar and parasellar region lesions spectrum includes a wide variety of conditions ranging from adenoma to empty sella syndrome, apoplexy, congenital or acquired condition¹⁻⁴. Other than adenoma, genetic causes of pituitary disease are increasingly recognized³.

Pituitary adenomas are not rare and account for 20% all intracranial tumors^{5,6}. Half of these secrete hormones, and half are microadenoma². Clinically non-functioning adenomas (NFPA) constitute 15–54% of all adenomas. Prolactinomas accounts for 32–66%, growth hormone secreting adenoma (acromegaly) account for 8–16%, adrenocorticotrophic hormone (ACTH)-secreting adenoma (Cushing's disease) forms 2–6%, and TSHoma accounts for less than 1%^{2,7}. These pituitary adenomas behave as typical or have a more aggressive to malignant behavior^{6,8}. They can cause mass effect, in addition to hypersecretion or hypopituitarism^{7,9}.

Advances in neuroradiology have opened the door for earlier and easier diagnosis of pituitary disease and other sellar and suprasellar lesions¹⁰.

The Faiha Specialized Diabetes, Endocrine, and Metabolism Center (FDEMC) in Basrah is a tertiary referral center receiving patients with pituitary diseases from most of Southern Iraq. The FDEMC is trying to adapt the three mission criteria of the pituitary center of excellence, which includes care and support for patients, fellowship training and contribution to pituitary disease research¹¹. To our knowledge, there are no studies on sellar and parasellar region lesions in Iraq.

This study aimed at a comprehensive description of pituitary disorders for patients from FDEMC in Basrah (Southern Iraq).

Methods

Study design

Retrospective data analysis of FDEMC database for the period from January 2012 through June 2017.

Inclusion criteria: We included all patients with pituitary disorders who have MRI pituitary regardless the age.

Exclusion criteria: patients with pituitary disorders with missed MRI.

Definition of variables

Sequences of pituitary MRI imaging were classified according to the international standard¹². Adenomas were classified as macroadenoma if these were 10 mm or more in size, while microadenoma if less than 10 mm and giant prolactinoma if these were 4 cm and above².

Pituitary adenoma (NFPA, prolactinoma, growth hormone secreting adenoma [acromegaly], and adrenocorticotrophic hormone (ACTH)-secreting adenoma) were defined according to the usual criteria^{2,8,12}.

Hypopituitarism, whether postoperative or in those with or without adenoma, was considered according to the hormonal assessment with basal and dynamic hormonal tests¹³.

Empty sella syndrome, whether primary or secondary to surgery or apoplexy, were considered based on MRI findings¹⁴.

Craniopharyngioma diagnosis was based on clinical behavior with MRI and pathological diagnosis.

Data analysis

Analysis was done in July 2017. All patients with labeling diagnosis of pituitary disease were included. Data were included on an Excel spreadsheet and transferred to SPSS for Windows, Version 23.0 (SPSS Inc., Chicago, USA).

Continuous variables were summarized as number and percentage and dichotomous variables as mean $\pm$ SD.

Ethics statement

The ethics committee of the Medical College in Basrah University approved the study design and the Center authorities agreed to review the patients data. At the time of registration in the Center, all patients included in this study approved the use of their clinical information for research purposes.

Results

A total of 232 patients were included in this study. Pituitary disorders were more common among women (Table 1). Those with macroadenoma were older than those with microadenoma with nearly equal gender prevalence of macroadenoma. Four patients died; two with growth hormone secreting adenoma (acromegaly) and advanced cardiovascular disease, and two with prolactinoma that caused hypopituitarism and adrenal failure.

Table 2 shows that pituitary adenoma constituted the bulk of pituitary disorders in this registry (67.2%). Growth hormone secreting adenoma (acromegaly) were the commonest adenoma seen in 41.0% followed by NFPA in 31.4% than prolactinoma in 26.9%. Hypopituitarism due to various causes was observed in 24.5% in this series. Empty sella syndrome, whether

Table 1. Pituitary disorders patients demography and characteristics.

			N (%); mean ±SD
Gender	All pituitary disorders	Men	84 (36.2)
		Women	148 (63.8)
	Pituitary adenoma*	Men	67 (43)
		Women	89 (57)
Age at registration, years		All	38.2±15.3
		Macroadenoma	42.5±14.9
		Microadenoma	34.8±14.7
Macroadenoma**		Men	51 (50.5)
		Women	50 (49.5)
Died			4

*Of 156 pituitary adenoma

**Of 101 macroadenoma

Table 2. Spectrum of pituitary disorders at the time of registry.

		N (%)
Pituitary adenoma		156 (67.2)
Growth hormone secreting adenoma (acromegaly)		64 (41.0)
Clinically non-functioning pituitary adenoma (NFPA)		49 (31.4)
Prolactinoma*		42 (26.9)
GH-secreting adenoma with hyperprolactinemia*		5
ACTH- secreting pituitary adenoma		2 (1.2)
Hypopituitarism		57 (24.5)
Empty sella syndrome	All	22 (9.4)
	Primary**	9
	Secondary	13
Diabetes insipidus		15
Apoplexy		3
Hyperprolactinemia	All	51
	No adenoma	12
Pituitary enlargement		3
Stalk lesions		1
Miscellaneous		***11
Craniopharyngioma		9 (3.9)
Sheehan syndrome		9 (3.9)
Meningioma		4 (1.7)
Rathke's cleft cyst		3
Total		232

*GH-secreting adenoma, 2 of them stain on biopsy for lactotroph cell

**Acromegaly in 4

*** Miscellaneous includes galactorrhea, hypogonadotropic hypogonadism, and acromegaloidism

primary or secondary, were seen in 9.4%. Craniopharyngioma and Sheehan syndrome were seen in 3.9% each. Meningioma based on MRI finding was been observed in 4 patients (1.7%).

In this study, 64.8% of pituitary adenoma were macroadenomas (Table 3). Macroadenoma was seen in 73.4% of acromegaly, 61.2% in NFPA and 62.0% of prolactinoma (of them six were giant prolactinoma).

In Table 4 we see hypophysectomy whether transsphenoidal or transcranial or both was performed in 45 patients with pituitary adenoma (28.8%). Stereotactic radiosurgery is done in 5 patients (3.2%) with pituitary adenoma. Growth hormone secreting adenoma (acromegaly) and prolactinomas were treated primarily with medical therapy (71.4% and 76.1% respectively).

Dataset 1. Description of patients included in the study
<http://dx.doi.org/10.5256/f1000research.13632.d197439>
Table 3. Pituitary adenoma according to the size.

	Microadenoma N (%)	Macroadenoma N (%)	Total
Pituitary adenoma	55 (35.2)	101 (64.8)	156
Growth hormone secreting adenoma (acromegaly)	17 (26.5)	47 (73.4)	64
Clinically non-functioning pituitary adenoma (NFPA)	19 (38.8)	30 (61.2)	49
Prolactinoma	16 (38)	26 (62.0)*	42
ACTH- secreting Pituitary adenoma	2 (100.0)	0	2

*Of them six giant Prolactinoma

Table 4. Type of treatment for pituitary adenoma.

		N (%)
Hypophysectomy-transsphenoidal		33 (21.1)
Hypophysectomy-transcranial		8 (5.1)
Hypophysectomy-transsphenoidal followed by transcranial or reverse or repeat same surgery, i.e., twice surgery		4 (2.5)
Stereotactic radiosurgery		5 (3.2)
Radiotherapy		1 (0.6)
Primary medical treatment	Growth hormone secreting adenoma (acromegaly)	46 (71.4)*
	Prolactinoma	32 (76.1)**
Total		156

*Of patients with acromegaly

**Of patients with prolactinoma

Discussion

All pituitary disorders and adenoma were more common among women in this study. The gender predominance among patients with pituitary adenoma is variable in the literature depending on hormone secretion and age of the patients, the size of the tumor and female dominance is not clear^{15,16}. However, female dominance has been seen in Saudi Arabia¹⁷ and one series from Argentina¹⁸. Those with macroadenoma tend to be older in age with no difference in the prevalence between men or women.

Seen in about two-thirds of patients, pituitary adenoma constituted the main bulk of pituitary disease in this study, which is compatible with reports in the literature¹⁶.

The commonest pituitary adenoma was growth hormone secreting adenoma (acromegaly), followed by NFPA and prolactinoma. This is entirely different from the literature on the prevalence of pituitary adenoma^{2,16,17,19}. This could be attributed to selection bias because only growth hormone secreting adenoma (acromegaly) patients are being referred, while NFPA and prolactinoma were treated by different specialties, such as neurosurgeons or gynecologists, without referral to a specialized Center like FDEMC. In Basrah, most cases of hyperprolactinemia were seen by a gynecologist because of amenorrhea and infertility, and the neurosurgeon follows patients with NFPA without referring them.

Hypopituitarism is prevalent in a quarter of this pituitary centre, from different causes, ranging from macroadenoma to hypophysectomy. Evaluation for hypopituitarism remains an integral part of the workup for any pituitary lesions because missing such diagnosis could be catastrophic^{9,13}. This figure is far higher than that of Saudi Arabia, which was 1.2%¹⁷.

Empty sella syndrome was seen in 9.4% of patients in this study, which can be primary or secondary to surgery or apoplexy. Empty sella syndrome needs an extensive workup to assess pituitary function²⁰.

Craniopharyngioma and Sheehan syndrome are two diseases with a different spectrum of age distribution, but they were seen at the same frequency in this cohort. Craniopharyngioma is a disease of childhood and adolescence²¹. Sheehan syndrome is supposed to be rare in developed countries, but is still seen in developing countries²².

Less than two thirds of adenoma in this study were macroadenomas. While in most series macroadenomas constitute 50% of the pituitary adenomas²; however in Canada, a similar finding has been seen compared with this study²³. Again this could be explained by referral bias in this study. In Saudi Arabia, microadenomas were more prevalent¹⁷.

For growth hormone secreting adenoma (acromegaly), more than two thirds were macroadenomas, which is established fact for all acromegaly^{2,24,25}.

NFPA was a macroadenoma and seen at around 60% in this study. A similar finding was seen in a previous series².

Prolactinomas were macroadenoma in around 60% of cases in this study. This differs from the literature, where more than 90% of prolactinomas were microadenomas^{2,18}.

Hypophysectomy-transsphenoidal as surgical treatment was done in one third of pituitary adenomas, while transcranial approach or stereotactic radiosurgery was contemplated in the minority. This is a typical approach for most of the pituitary adenomas^{2,26}. For growth hormone secreting adenoma (acromegaly), the primary treatment in this study was medical treatment in about two thirds of individuals. This is contrary to literature where surgery is the main mode of therapy²⁶. The explanation is that we are just building a new neurosurgery unit for pituitary glands over the last few years, and in the future, surgery of pituitary is supposed to improve, and early referral will be the best.

For prolactinoma, primary medical treatment was done in two thirds of patients, while it should be the main treatment of choice in more than 90%, as seen in previous literature²⁶.

Malignant disease metastasizing to the pituitary is not observed in this study because they are not referred from Oncology Center in Basrah.

Study limitation

This study supposes to involve most of the pituitary disease patients in Basrah because the Center is a tertiary referral center. However, due to referral bias among some neurosurgeons and gynecologists, we cannot guarantee that the data includes all patients with this condition in Basrah.

Conclusion

Pituitary adenomas constituted the bulk of pituitary disorders in Basrah. Growth hormone secreting adenoma (acromegaly) is the most frequent adenoma followed by NFPA and prolactinoma due to referral bias. A change in the practice of pituitary adenoma treatment is needed.

Data availability

Dataset 1: Description of patients included in the study [10.5256/f1000research.13632.d197439](https://doi.org/10.5256/f1000research.13632.d197439)²⁷

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Acknowledgments

All authors are thankful to the medical staff of FDEMC for their contribution and support.

References

1. Glezer A, Bronstein MD: **Pituitary apoplexy: pathophysiology, diagnosis and management.** *Arch Endocrinol Metab.* 2015; **59**(3): 259–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Molitch ME: **Diagnosis and Treatment of Pituitary Adenomas: A Review.** *JAMA.* 2017; **317**(5): 516–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Larson A, Nokoff NJ, Meeks NJ, *et al.*: **Genetic causes of pituitary hormone deficiencies.** *Discov Med.* 2015; **19**(104): 175–83.
[PubMed Abstract](#)
4. Messerer M, Dubourg J, Raverot G, *et al.*: **Non-functioning pituitary macro-incidentomas benefit from early surgery before becoming symptomatic.** *Clin Neurol Neurosurg.* 2013; **115**(12): 2514–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Mehta GU, Lonser RR: **Management of hormone-secreting pituitary adenomas.** *Neuro Oncol.* 2017; **19**(6): 762–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Chatzellis E, Alexandraki KI, Androulakis II, *et al.*: **Aggressive pituitary tumors.** *Neuroendocrinology.* 2015; **101**(2): 87–104.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Narendra BS, Dharmalingam M, Kalra P: **Acromegaloïdism Associated with Pituitary Incidentaloma.** *J Assoc Physicians India.* 2015; **63**(6): 79–82.
[PubMed Abstract](#)
8. Dai C, Feng M, Liu X, *et al.*: **Refractory pituitary adenoma: a novel classification for pituitary tumors.** *Oncotarget.* 2016; **7**(50): 83657–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Higham CE, Johannsson G, Shalet SM: **Hypopituitarism.** *Lancet.* 2016; **388**(10058): 2403–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Fabian UA, Charles-Davies MA, Fasanmade AA, *et al.*: **Male Sexual Dysfunction, Leptin, Pituitary and Gonadal Hormones in Nigerian Males with Metabolic Syndrome and Type 2 Diabetes Mellitus.** *J Reprod Infertil.* 2016; **17**(1): 17–25.
[PubMed Abstract](#) | [Free Full Text](#)
11. McLaughlin N, Laws ER, Oyesiku NM, *et al.*: **Pituitary centers of excellence.** *Neurosurgery.* 2012; **71**(5): 916–24; discussion 24–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Chanson P, Raverot G, Castinetti F, *et al.*: **Management of clinically non-functioning pituitary adenoma.** *Ann Endocrinol (Paris).* 2015; **76**(3): 239–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Kim SY: **Diagnosis and Treatment of Hypopituitarism.** *Endocrinol Metab (Seoul).* 2015; **30**(4): 443–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Spaziante R, Zona G, Testa V: **Primary empty sella syndrome.** *Surg Neurol.* 2003; **60**(2): 177–8; author reply 178.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. McDowell BD, Wallace RB, Carnahan RM, *et al.*: **Demographic differences in incidence for pituitary adenoma.** *Pituitary.* 2011; **14**(1): 23–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Drange MR, Fram NR, Herman-Bonert V, *et al.*: **Pituitary tumor registry: a novel clinical resource.** *J Clin Endocrinol Metab.* 2000; **85**(1): 168–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Aljabri KS, Bokhari SA, Assiri FY, *et al.*: **The epidemiology of pituitary adenomas in a community-based hospital: a retrospective single center study in Saudi Arabia.** *Ann Saudi Med.* 2016; **36**(5): 341–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Day PF, Loto MG, Glerean M, *et al.*: **Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina.** *Arch Endocrinol Metab.* 2016; **60**(6): 554–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Lake MG, Krook LS, Cruz SV: **Pituitary adenomas: an overview.** *Am Fam Physician.* 2013; **88**(5): 319–27.
[PubMed Abstract](#)
20. Ghatnatti V, Sarma D, Saikia U: **Empty sella syndrome - beyond being an incidental finding.** *Indian J Endocrinol Metab.* 2012; **16**(Suppl 2): S321–3.
[PubMed Abstract](#) | [Free Full Text](#)
21. Müller HL: **Craniopharyngioma.** *Handb Clin Neurol.* 2014; **124**: 235–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Karaca Z, Laway BA, Dokmetas HS, *et al.*: **Sheehan syndrome.** *Nat Rev Dis Primers.* 2016; **2**: 16092.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Imran SA, Yip CE, Papneja N, *et al.*: **Analysis and natural history of pituitary incidentalomas.** *Eur J Endocrinol.* 2016; **175**(1): 1–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Lavrentaki A, Paluzzi A, Wass JA, *et al.*: **Epidemiology of acromegaly: review of population studies.** *Pituitary.* 2017; **20**(1): 4–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, *et al.*: **The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes.** *J Clin Endocrinol Metab.* 2016; **101**(11): 3997–4004.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Al-Dahmani K, Mohammad S, Imran F, *et al.*: **Sellar Masses: An Epidemiological Study.** *Can J Neurol Sci.* 2016; **43**(2): 291–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Mansour AA, Alhamza AH, Almomin AM, *et al.*: **Dataset 1 in: Spectrum of Sellar and Parasellar Region Lesions: A retrospective study from Basrah, Iraq.** *F1000Research.* 2018.
[Data Source](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 09 July 2018

<https://doi.org/10.5256/f1000research.16733.r35342>

© 2018 Al-Dahmani K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Khaled Mohammed Al-Dahmani

¹ Division of Endocrinology, Tawam Hospital, Al Ain, United Arab Emirates

² Department of Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Abu Dhabi, United Arab Emirates

While the authors addressed some of the raised comments, I see a need for the following:

1. Simplify Table 2 into 4 main groups as mentioned before. It is understandable that patients with seller masses may also have hyperprolactinemia and hypopituitarism. These cases should be counted under sellar masses category and not included under hyperprolactinemia and hypopituitarism categories. This will clarify the spectrum of pituitary disorders seen in this study and will be easy to compare if similar studies from other centers were to be published in the future.
2. Under "miscellaneous" group, galactorrhea and acromegaloidism need not to be included in the study unless there is a pituitary disorder to explain such diagnosis. The other case(s) of hypogonadism should be counted under the category of hypopituitarism (which is already present as a category by itself).
3. For Table 3, the total number of adenomas (156) should exactly equal the sum of all adenoma subtypes. If a patient has a mixed adenoma (GH & PRL secreting adenoma) it should be counted as 1 adenoma under GH category for example and not included both.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pituitary, thyroid

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 14 June 2018

<https://doi.org/10.5256/f1000research.14810.r34531>

© 2018 Al-Dahmani K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Khaled Mohammed Al-Dahmani

¹ Division of Endocrinology, Tawam Hospital, Al Ain, United Arab Emirates

² Department of Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Abu Dhabi, United Arab Emirates

The study by Mansour AA et al. is an important contribution to the limited pituitary research in the middle East and North Africa (MENA) region.

The following points need further modifications/clarifications;

- Sellar and parasellar region lesions usually refers to structural abnormalities and do not necessarily include other pituitary pathologies like hyperprolactinemia and hypopituitarism. Therefore, I suggest using the term "pituitary disorders" instead; more comprehensive.
- The inclusion of patients needs further clarifications in the "Method" section. what diagnoses were looked for?
- Pituitary adenoma includes all functioning and non-functioning pituitary tumors. In some part of the text, it was used separately from its subtype (see paragraph; Definition of variables). Maybe just typo.
- Table (2) needs to be simplified. The total number of patients should equal clearly equal 232. I suggest using 3-4 categories only; Sellar masses/abnormalities, Hyperprolactinemia, hypopituitarism and others.
- The "miscellaneous" cases need to be mentioned; what diagnoses are here?
- Table 3 the sum of patient with pituitary adenoma subtypes are not equal to the total number of cases.
- In the conclusion, "A change in the practice of adenoma treatment is needed" is very general. Based on the presented data, change in the management of GH secreting adenomas is more specific and relevant.
- Additional language editing will further enhance the manuscript.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pituitary, thyroid

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 19 Jun 2018

Abbas Mansour, Diabetes, Endocrine and Metabolism Division, Department of Medicine, Basrah College of Medicine, Hattin post office. P.O Box: 142, Iraq

The study by Mansour AA et al. is an important contribution to the limited pituitary research in the middle East and North Africa (MENA) region.

The following points need further modifications/clarifications;

- Sellar and parasellar region lesions usually refers to structural abnormalities and do not necessarily include other pituitary pathologies like hyperprolactinemia and hypopituitarism. Therefore, I suggest using the term "pituitary disorders" instead; more comprehensive.

Done

- The inclusion of patients needs further clarifications in the "Method" section. what diagnoses were looked for?

Retrospective data analysis of FDEMC database for the period from January 2012 through June 2017.

Inclusion criteria: We included all patients with pituitary disorders who have MRI pituitary regardless the age .

- Pituitary adenoma includes all functioning and non-functioning pituitary tumors. In some part of the text, it was used separately from its subtype (see paragraph; Definition of variables). Maybe just typo.

Done

- Table (2) needs to be simplified. The total number of patients should equal clearly equal 232. I suggest using 3-4 categories only; Sellar masses/abnormalities, Hyperprolactinemia, hypopituitarism and others.
Its cant be 232 because some may have more than one diagnosis
 - The "miscellaneous" cases need to be mentioned; what diagnoses are here?
Miscellaneous includes galactorrhea, hypogonadotropic hypogonadism, and acromegaloidism
 - Table 3 the sum of patient with pituitary adenoma subtypes are not equal to the total number of cases.
GH-secreting adenoma, 2 of them stain on biopsy for lactotroph cell
GH-secreting adenoma with hyperprolactinemia in 5 patients
 - In the conclusion, "A change in the practice of adenoma treatment is needed" is very general. Based on the presented data, change in the management of GH secreting adenomas is more specific and relevant.
A change in the practice of pituitary adenoma treatment is needed.
All adenomas treatment needed reevaluation .
 - Additional language editing will further enhance the manuscript.
Done
- Competing Interests:** No competing interests were disclosed.

Reviewer Report 30 April 2018

<https://doi.org/10.5256/f1000research.14810.r32887>

© 2018 Al-Toma A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abdul Al-Toma

Department of Internal Medicine, Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, The Netherlands

Dr. Mansour and co-authors investigated the Spectrum of pituitary disease (Sellar and Parasellar Region Lesions) in a large cohort of patients from a tertiary referral center in the southern region of Iraq. This center receives patients with pituitary diseases from most of Southern Iraq, a population of 6-8 million.

The authors provided a well written retrospective analysis of the study population. The manuscript is focused on providing an attractive epidemiological description of the studied patients.

Abstract section: concise text and states clearly the objective of the report. In their conclusion

they stated that a change in practice of adenoma treatment is needed. It would be more informative if they provide some data on how they reached to this conclusion. A minor correction: the following 2 sentences need to be separated by full stop mark instead of comma (*Pituitary adenoma constituted the bulk of sellar and parasellar region lesions, growth hormone secreting adenoma is the most common adenoma followed by NFPA and prolactinoma due to referral bias.*)

The following sections are well written and data were clearly presented:

Methods and results. In addition they included an appropriate Statistical analysis. However, minor English language edition is needed.

The discussion section described the study results in comparison with recent literature. Recent literature has been adequately addressed. The authors stated the limitation of their manuscript clearly. It would be interesting to provide some information on the prognosis of their study patients, both for surgically or medically treated patients.

The references are clearly presented and conform the current standards.

The tables are clearly written.

Minor comments: although the manuscript is well written, however some revision of the English text needs to be done.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research